cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Doppler Flow From the Femoral Artery as a Reflection of Cardiac Flow in a Vascular Fluid Test

In order to identify the responding patients with vascular filling test, this research aims to compare the performance of the increased flow in the femoral artery to the performance of the blood pressure increase.

The reference measurement will increase cardiac output measured by ultrasound.

It is notable that in the intensive care patient, the ultrasound measurement of cardiac flow is not always possible, especially in case of mechanical ventilation, often responsible for air interposed between the ultrasound probe and the heart, thus stopping the ultrasound. Use the blood pressure increase as a reflection of the increase in cardiac flow induced by fluid replacement is not a fully satisfactory alternative since its performance is at best just acceptable.

Flow measurement in the femoral artery could be an attractive alternative to the cardiac output measurement as:

* It is easy: the femoral vascular ultrasound is booming with resuscitators, including the laying of intravascular catheter or thrombosis diagnosis.
* It is painless: it is based on the application of the ultrasound probe on the root of the thigh for less than 5 minutes.
* It is not subject to limitations echogenicity by interposition of air (except in exceptional circumstances)
* It measures the same physiological parameter (arterial flow) as measuring ultrasound cardiac output (based on measurement of the flow at the outflow tract of the left ventricle).

Pathophysiology study, multicenter (conducted in three French ICUs), open, prospective in order to evaluate the flow doppler from the femoral artery as a reflection of cardiac flow in a vascular fluid test in patient with signs of acute circulatory failure in intensive care unit.

Eligibility Criteria:
Inclusion Criteria:

Patient hospitalized in intensive care and affiliated to a social security system

* Intra-arterial catheter already in place and operational
* Stability blood pressure for 5 min (no change in mean arterial pressure\> 10%, no increase in dose catecholamine)
* Presence of at least one sign of acute circulatory failure from:

  * Low blood pressure (mean arterial pressure \<65 mmHg and / or systolic \<90 mmHg)
  * tachycardia\> 120 bpm without other obvious cause a circulatory failure
  * Oliguria \<1 ml / kg during the last hour suggestive of circulatory failure
  * blood Hyperlactataemia\> 2 mmol / l without other obvious cause a systemic circulatory failure (lactate will not be measured for the purposes of the study)
  * Smear
  * ongoing catecholamine Administration
  * Another sign justifying, according to the doctor in charge, vascular filling test (capillary refill time elongated, others ...)
* The doctor in charge has prescribed a fluid loading test, regardless of the needs of the study.

Non inclusion criteria:

Clear contraindication to the femoral artery Doppler (wound or burn the groin, for example)

* Complete occlusion of the femoral artery or 2 of the aorta requiring or having required a vascular bypass
* Pregnant woman
* Minor
* Major Trust
e-BioMatrix PostMarket Registry

The purpose of this registry is to capture clinical data of the BioMatrix™ and BioMatrix Flex™ (Biolimus A9™-Eluting) stent systems in relation to safety and effectiveness.

Prospective, multi-center registry to be conducted at 60-70 international interventional cardiology centers. All patients will be followed for up to 3 years.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18 years
2. Patients that need a treatment with either a BioMatrix™ or a BioMatrix Flex™ drug-eluting stent
3. Presence of one or more coronary artery stenoses in a native coronary artery or a saphenous bypass graft from 2.25 to 4.0 mm in diameter that can be covered with one or multiple stents
4. No limitation on the number of treated lesions, and vessels, and lesion length

Exclusion Criteria:

1. Inability to provide informed consent
2. Patients needing additional stent NOT of the Biolimus A9™-eluting stent type
3. Patients receiving next to the Biolimus A9™-eluting stent also other coronary vascular interventions, for example dilation
4. Patients receiving both the BioMatrix™ and the BioMatrix Flex™ stent during index and/or staged procedure
Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

The purpose of the program is to study and characterize the outcome of burn injury with particular attention to improving the rehabilitation of burn survivors, including children. Various agents are assessed for effectiveness on long term burn outcome, such as growth hormone, oxandrolone, propranolol,ketoconazole, inhospital exercise and home exercise.

The University of Texas Medical Branch(UTMB) project improves outcomes for severely burned children by instituting and evaluating two modifications to traditional rehabilitation: (1) an intensive rehabilitation program including active resistance exercise; (2) long term administration of anabolic agents.

Effectiveness is assessed by comparison with functional outcomes achieved in traditional outpatient rehabilitation programs. Results indicate improvement in strength, endurance and bone density with these modifications. The project also maintains a longitudinal database that includes measures of cardiopulmonary function, growth and maturation, bone density, range of motion, and psychosocial adjustment.

Eligibility Criteria:
Inclusion Criteria:

* Burn 30% Total Body Surface Area (TBSA) or greater
* Ages 0-80 yrs
* Negative pregnancy test
* Informed consent

Exclusion Criteria:

* Untreated malignancy, known history of AIDS, Aids Related Complex, HIV
* Recent history of myocardial infarction (6 wks)
* Tuberculosis, arthritis, cirrhosis, hyperlipidemia, bone or endocrine diseases, autoimmune diseases
* Chronic glucocorticoid or non steroidal anti inflammatory drug therapy
* Diabetes mellitus prior to burn injury
* Renal insufficiency (defined by creatinine \>3.0 mg/dl)
* Hepatic disease (bilirubin \> 3.0 mg/dl)
Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases

The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are:

Does HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients?

Participants will:

Receive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.

Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD) patients who meet our principles would be randomized into 2 groups: the HBOT group and CON group. The entire project is not blinded. In HBOT group, participants will receive HBOT for 20 times in 1 month (2.0ATA, 60min), which is the common setting in clinical use.The CON group, which means the control group, recerives regular drug, like liver-protective drugs and hypoglycemic drugs. The visiting times are week 0 (starting of the project), week 4 (ending of the therapy), week 28 (6 months after the therapy), when participants get checkups and tests. The primary outcome of our study are the change of liver fat content and stiffness in Fibroscan. The secondary outcomes invovle changes of liver function enzymes and metabolism.

Eligibility Criteria:
Inclusion Criteria:

* Metabolic dysfunction-associated steatotic liver disease patients

Exclusion Criteria:

* Participants are unfit for hyperbaric treatment.
* Participants with prior oxygen therapy within the last 6 months.
* Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency.
* Participants with severe organ dysfunctions or malignant tumors.
* Participants have weight loss plan or major operations within the last 6 months.
* Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial.
* Participants are pregnant or lactating.
* Participants with claustrophobia or that cannot decompress properly.
Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis

To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis


Eligibility Criteria:
Key Inclusion Criteria:

* Diagnosis of multiple sclerosis (MS) of any type.
* MS diagnosis at least 6 months prior to screening.
* Stable MS with no relapse within 3 months prior to screening.
* Treated or untreated spasticity due to MS for at least 3 months prior to screening, not wholly relieved with antispasticity medications.

Key exclusion criteria:

* Patients with symptoms of spasticity not due to MS.
* Patients taking three or more different anti-spasticity medications.
* Acute MS exacerbation requiring treatment within 3 months of the Screening Visit.
* Initiation of, or the discontinuation of interferon beta or any other disease modifying therapy for MS within 3 months of the Screening Visit.
* Use of baclofen pump at any time.
* Wheelchair or bed-bound patients.
Assessment of Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer Patients With High Surgical Difficulty

While robotic gastrectomy (RG) is increasingly used in gastric cancer surgery, its potential advantages over laparoscopic gastrectomy (LG) in high surgical difficulty (HSD) cases remain debated.

This retrospective cohort study included 3,534 patients with gastric cancer who underwent radical gastrectomy at eight high-volume hospitals. HSD was defined by any of the following criteria: operative time exceeding the third quartile, intraoperative estimated blood loss ≥ 400 mL, or conversion to open surgery. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were conducted to compare short- and long-term outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Patients with postoperatively histologically confirmed T1-4aN0-3bM0 gastric adenocarcinoma who underwent RG or LG

Exclusion Criteria:

* Remnant gastric cancer
* Previous malignant
* ASA class \>3
* Use of indocyanine green
* Neoadjuvant chemotherapy
* Loss to follow-up
* Combined resection
The Effect of Routine and Random Pacifier Use Methods in Preterm Infants

The aim of this study is to determine the effect of the routine 5-min pacifier use before feeding and the random 30-min pacifier use independent from feeding during the day on the transition to bottle feeding process in preterm infants.

Preterm infants, may most frequently experience feeding difficulties as a result of lower oral-motor tone, poor coordination during sucking-swallowing-respiration, sleepy behavior, gastrointestinal dysmotility and immature sucking pressure and being unable to sustain their physiological values at a normal level during feeding. In the literature, it is reported that approximately 82% of preterm infants have an oral feeding difficulty. As a consequence, it is a very complex process to acquire a safe and effective feeding skill and preterm infants need support in the weeks after birth until participants develop skills that are necessary for oral feeding and complete a successful transition to total oral feeding independent from orogastric catheter.

Although studies have stressed positive effects of the Non-nutritive sucking (NNS) intervention on feeding performance, it is reported that there is a need for more comprehensive randomized controlled studies revealing the use frequency, duration or effect of time.

In the Neonatal Intensive Care Unit (NICU) where the study will be conducted, an appropriate method is chosen for preterm infants based on their general condition and the feeding transition stages are determined incrementally with repetitive follow-ups during feeding. The routine 5-min pacifier use method before feeding and the random 30-min pacifier use method during the day will be applied to newborns who have enteral feeding. Newborns who already use pacifier independent from feeding during the day in the clinic and to whom these methods are applied, will comprise the control group. In order to ensure a homogeneous application in the control group, the pacifier use duration will be limited to 30 minutes. Pacifier use durations have been determined in line with the literature examining the contribution of pacifier use to the feeding of preterm infants. Newborns, to whom the routine 5-min pacifier use method is applied before each feeding, will comprise the experimental group. All newborns included in the study will be followed until participants are discharged.

Eligibility Criteria:
Inclusion Criteria:

Preterm infants;

* Whose legal representatives agree to take part in the study and sign the informed consent form,
* Who have a stable clinical picture,
* Who are on the first day of enteral feeding will be included in the study.

Exclusion Criteria:

Preterm infants;

* Who have a comorbidity,
* Who are intubated,
* Who have an inherent anomaly,
* Who have parenteral feeding will not be included in the study.
Transcutaneous Electrical Stimulation of the Vagus Nerve

This study evaluate the cognitive functions of patient after hip or kneel replacement.Half of the patient will receive transcutaneous vagus nerve electrical stimulation during the surgery while the other half will get placebo therapy


Eligibility Criteria:
Inclusion Criteria:

* over 65 years old
* ability to communication
* hip or kneel replacement
* willing to participate in the study
* ASA I-II

Exclusion Criteria:

* with cerebral disorders or disease
* cognitive impairment before surgery
* with mental disease
* unable to communication
* severe eyes or ears impairment
* surgery performed in the past 30 days
* Bradycardia，II°AVB，III°AVB，severe heart, liver and kidney dysfunction
* severe skin disease
* refuse to enter the study
Accuracy of Different Scoring Systems for Predicting Successful Induction of Labor

Induction of labour (IOL) nowadays is a common procedure in obstetric practice. Presently, IOL is done for 20% of pregnancies for various maternal and fetal indications and nearly 20% of labour inductions end up in caesarean deliveries. The success of IOL mainly depends upon "favourability" of the cervix which is usually assessed by manual examination and Scored as Bishop Score. However, this method is limited by subjectivity and reproducibility and though done in all the patients prior to IOL, several studies have demonstrated poor correlation between Bishop Score and outcome of IOL


Eligibility Criteria:
Inclusion Criteria:

1. Singleton pregnancy.
2. Pregnant ≥ 37 weeks gestation.
3. Fetus with longitudinal lie and vertex presentation.
4. Intact membranes.
5. No vaginal bleeding.

Exclusion Criteria:

1. Patients with previous cesarean delivery.
2. Previous uterine surgery.
3. Antepartum hemorrhage.
4. Cephalopelvic disproportion.
5. Category II or III non-stress test.
6. Malpresentation.
7. Intrauterine fetal death.
8. Fetal growth restriction.
9. Fetuses with major congenital malformations
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults

To evaluate the safety and pharmacokinetic characteristics of AJU-C711 in healthy adults


Eligibility Criteria:
Inclusion Criteria:

1. Healthy adult volunteers aged ≥ 19-year-old
2. Weight ≥ 50kg (man) or 45kg (woman), with calculated body mass index(BMI) of 18 to 30 kg/m2
3. Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings
4. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serum, urine test) and 12-lead ECG results during screening tests

6. Those who agree to contraception during the participation of clinical trial 7. Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial

Exclusion Criteria:

1. Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug
2. Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days
3. Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study
4. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug
5. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass/week, Women - 14 glass/week (1 glass: Soju 50 mL, liquor: 30mL or Beer 250mL)
6. Those who has under

   * Those who are hypersensitive to component of the Investigational product and have the medical history
   * Those with active liver disease or persistent elevation of aminotransferase levels of unknown
   * Those with severe hepatic impairment or biliary atresia and cholestasis
   * Those taking cyclosporin
   * Those with myopathy
   * Those who has a disease history of diabetic mellitus, nephropathy, biliary obstruction, dihydropyridine sensitivity, angioedema
   * Those who has Genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
7. Those who has a history of mental illness
8. Those who are deemed unfit by the investigators to participate in the clinical trial for other reasons
9. Women who are pregnant or who may be pregnant and breastfeed
Dual-plane Ultrasound Imaging During Vascular Access Procedures

Researchers are evaluating the clinical efficiency of utilization of a dual-plane simultaneous view ultrasound probe (Butterfly iQ+; Butterfly Network, Inc.) during arterial catheter placement in the operating room


Eligibility Criteria:
Inclusion criteria

* Patient: Elective surgical patients requiring non-emergent ultrasound-guided radial arterial catheter placement
* Providers: Anesthesia providers to include trainees, certified registered nurse anesthetists (CRNA) and attending anesthesia providers.

Exclusion Criteria

* Patient
* Pregnant
* Patients in a moribund state or palliative care only
* Vulnerable patients (i.e. Severe mental handicap, non-decisional)
* History of peripheral arterial disease
* Placement of arterial catheter without ultrasound guidance
* Provider: Medical students or CRNA students.
Dynamic Monitoring of Circulating microRNA Changes in Patients With or Without Multiple Organ Failure

The objectives are to:

1. validate a panel of tissue-specific miRNAs that are differentially expressed in the plasma of patients with and without multiple organ failure.
2. investigate the dysregulation of circulating miRNA panel and their prognostic and predictive values in clinical outcomes in identifying patients at high risk for mortality and multiple organ failure.

This trial involves peripheral blood sampling from subjects at their earliest presentation and remaining stays in the hospitalization in the emergency department. The investigators will develop panels of miRNAs that are specific indicator of early onset of major organ failures, and correlate clinical outcomes with these miRNAs.

The ICU patients with multiple organ failure in sponsor's institutes will be enrolled in this observational cohort of investigation. Whole blood samples will be separated immediately into plasma for storage. The participants will have their 2nd and 3rd samples obtained at 24-48 hours and 48-72 hours respectively. The schedule of most of sampling schedule is designed in concordance with the ICU routines to avoid extra burdens on patients. The plasma samples will be used as prognostic markers in prognostic and predictive values in identifying patients at high risk for mortality and multiple organ failure. Patients who are discharged will be tracked for any clinical recurrence of the diseases every 28 days to assess the diagnostic accuracy of the miRNA biomarkers that are measured.

The 2nd objective will be assessed by measuring the concentration of miRNAs in normal patients without multiple organ failure.

The circulating miRNAs will be detected directly from 1 - 5 ul of plasma samples with the miRFLP assay. This capillary electrophoresis-based miRNA quantification method detects multiple miRNAs in absolute copy number in smaller sample signature with negligible batch to batch variation, thus providing a standard miRNA detection method.

Eligibility Criteria:
Inclusion Criteria for subjects:

* Adults 18 years and above
* Has condition related to ICU enrollment cause

Exclusion Criteria for subjects:

* Age below 18 years
* Known pregnancy
* Treating physician deems aggressive care unsuitable
* Unable to provide informed consent or comply with study requirements

Inclusion criteria for normal controls:

• Adults 18 years and above

Exclusion criteria for normal controls:

* Underlying chronic inflammatory condition (e.g. inflammatory bowel disease)
* Underlying autoimmune disease (e.g. rheumatoid arthritis, systemic lupus erythematosus)
* Pre-existent liver disorder
* User of any prescript medicine or over the counter drugs in prior 7 days.